Did Merck Make a Mistake With a Key FDA Filing?

Merck (NYSE:MRK) has won multiple U.S. Food and Drug Administration (FDA) approvals for its blockbuster cancer drug Keytruda. However, the big drugmaker seems to have run into a roadblock with its latest regulatory submission for the immunotherapy. In this Motley Fool Live video recorded on Feb. 10, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Merck made a mistake by moving forward too quickly with its FDA filing.